China National Registry of Neuro-Inflammatory Diseases: a Prospective Cohort Study

What this Trial Is About

Central nervous system idiopathic inflammatory demyelinating diseases (IDD), including multiple sclerosis (MS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and acute disseminated encephalomyelitis (ADEM), are autoimmune conditions that cause damage in the brain, spinal cord, and optic nerves. This research aims to build a large national registry of Chinese patients with IDD to better understand the natural course, disability progression, and prognosis of these diseases. The study will also explore biological and imaging markers that predict disease progression and treatment effects. This is a prospective, observational, multicenter cohort study that collects detailed clinical, demographic, and medical data from patients diagnosed with IDD according to established criteria. Treatments are not limited by the study and follow current guidelines, including common use of high-dose intravenous steroids during acute stages and immunomodulatory therapies during remission. Data will be gathered regularly over up to five years, including clinical assessments, imaging, and biological tests. Participants will be followed routinely from enrollment, with assessments including relapse rates, disability scores, brain and spinal cord MRI changes, visual acuity tests, retinal nerve fiber thickness, cognitive function, and serum markers. Safety and tolerability will also be monitored. The study plans to enroll 10,000 patients, with continuous data collection to understand long-term treatment outcomes and disease progression in Chinese IDD patients.

China National Registry of Neuro-Inflammatory Diseases